The FDA has approved a new drug test for ALS, amyotrophic lateral sclerosis, which will be conducted by BrainStorm Cell Therapeutics at the Mayo Clinic and Massachusetts General Hospital in Boston in a double-blind study.
Phase II as it is known will test how well patients tolerate the new stem cells that will be injected into them and its efficacy. The Connell O’Reilly Cell Manipulation Core Facility of Israel will make the cells to be used in the study.
So far, researchers say earlier Phase I test concluded this will be well tolerated and provide significant improvements in ALS patients.
ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord and is sometimes called Lou Gehrig’s Disease.